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The aim of this study was to evaluate the pharmacokinetics of meta(tetrahydroxyphenyl)chlorin (mTHPC) on different tissues
of interest in a hamster tumour model and to conﬁrm our earlier animal studies on semi-quantitative ﬂuorescence microscopy.
The results obtained by three different evaluation methods were compared: in vivo spectroﬂuorometry, ex vivo ﬂuorescence
microscopy and chemical extraction of
14C-labelled mTHPC. Following intracardiac injection of 0.5 mg kg
71 mTHPC, groups
of ﬁve tumour-bearing animals were used for in situ light-induced ﬂuorescence spectroscopy. Afterwards, the biopsies were
taken and snap frozen for ﬂuorescence microscopy. The presence of radioactivity in serum and tissues was determined after
chemical digestion in scintillation ﬂuid using a scintillation counter. For each analysed tissue, a good correlation was observed
between the three evaluation methods. The highest ﬂuorescence intensity and quantities of mTHPC were observed between
12 and 24 h in liver, kidney, serum, vascular endothelium and advanced neoplasia. The majority of mTHPC was found at
around 48 h in smooth muscle and at 96 h in healthy cheek pouch mucosa and early malignant lesions. The lowest level of
mTHPC was noted in striated muscle at all times. No selectivity in dye localisation was observed between early squamous cell
carcinoma and healthy mucosa. Soon after the injection, a signiﬁcant selectivity was noted for advanced squamous cell
carcinoma as compared to healthy cheek pouch mucosa or striated muscle. A signiﬁcant difference in mTHPC localisation and
quantity was also observed between striated and smooth muscle during the ﬁrst 48 h following the injection. Finally, this study
demonstrated the usefulness of non-invasive in situ spectroscopic measurements to be performed systematically prior to
photodynamic therapy as a real-time monitoring for each treated patient in order to individualise and adapt the light
dosimetry and avoid over or under treatments.
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Photodynamic therapy (PDT) involves the administration of a
photosensitiser (PS) and the local illumination of the target with
the light of a wavelength corresponding to an absorption peak of
the administered drug. The absorption of the light energy by a PS
induces a photochemical reaction leading to the damage of the illu-
minated tissue (Gibson et al, 1994). Over the past two decades, this
minimally invasive treatment modality has continued to be evaluated
for its effectiveness in eradication of malignant (Biel, 1995; Grosjean
et al, 1996a; Ris et al, 1996) and non-malignant lesions (Hsiang et al,
1993; Haimovici et al, 1997; Trauner et al, 1998). Amount and time-
dependent localisation of the photosensitiser in various tissues play a
key role in the mechanism of destruction induced by PDT. The
knowledge of pharmacokinetics and tissue afﬁnity of the PS helps
to give further insight into fundamental phototoxicity mechanisms
such as vascular vs cellular damage and their relative importance
to tissue destruction. Photodynamic therapy with meta(tetrahydrox-
yphenyl)chlorin (mTHPC) has been shown in clinical trials to be a
safe and effective treatment of early malignancy in the upper aero-
digestive tract, the bronchi and the oesophagus (Grosjean et al,
1996b; Savary et al, 1997). Numerous studies have shown that
mTHPC, like other anti-cancer drugs (McLoed and We, 1995), has
high inter-patient variability for accumulation of the drug in normal
or malignant tissues (Braichotte et al, 1996; Glanzmann et al, 1998).
This variability is probably a major factor in the large range of tissue
responses to PDT in different patients who have undergone treat-
ment under identical conditions (e.g., drug dose, light dose, light
dose rate, time delay after drug administration). The tissue response
to PDT could be apparently improved by taking into account the
real-time PS concentration determined by light-induced ﬂuorescence
spectroscopy (LIFS). This non-invasive in situ technique enables the
treatment conditions to be adapted and the light dose to be indivi-
dualised for each treated patient to avoid over or under treatment
(Wagnie `res et al, 1998). To clarify these in vivo data, and to introduce
LIFS systematically in situ before each PDT, one of the main goals of
this study was to conﬁrm and correlate the data obtained by LIFS
with two other evaluation methods.
Our earlier animal studies on semi-quantitative ﬂuorescence
microscopy (FM) (Andrejevic et al, 1996; Andrejevic Blant et al,
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www.bjcancer.com2000) have shown the much lower uptake and retention of
mTHPC in striated muscle as compared to normal oral mucosa,
squamous cell carcinoma (SCC) and smooth muscle. These ﬁnd-
ings are of major importance in clinical PDT for treating SCCs
with unfavourable localisations safely, such as the base of the
tongue or the oesophagus. Another goal of this study was to
compare our earlier data on FM to those obtained by in vivo spec-
troﬂuorometry and chemical extraction of
14C-labelled mTHPC in
the hamster squamous cell carcinoma model. The pharmacokinetic
pathway and the tissue afﬁnity of mTHPC, determined by three
different evaluation methods are of interest for a better under-
standing of the mechanisms of distribution, retention and tissue
damage after mTHPC-PDT.
MATERIALS AND METHODS
Animal model
Female Syrian hamsters (BRL, Fuellinsdorf, CH) weighing 140–
160 g, housed at room temperature with 12 h light/dark cycle were
used in this study. Free access to food and drinking water was
allowed throughout the experiments. The animals were divided
into two groups (early and advanced SCC) prior to chemically
induced carcinogenesis. Early and advanced SCCs were chemically
induced by topical application of 5% oily DMBA (Sigma Chemi-
cals, Co., St. Louis, MO, USA) solution in the hamster’s left
cheek pouch mucosa three times weekly during 10–12 weeks (early
SCC) and 14–16 weeks (advanced SCC), respectively. The contral-
ateral buccal pouch mucosa, which was not painted with DMBA,
served as the healthy mucosa control (Figure 1A). The animals
were regularly checked to document the development of neoplastic
changes. Up to ﬁve tumour-bearing animals were used for each
analysed time point. In vivo measurements were performed under
intraperitoneal anaesthesia (Ketalar 150 mg kg
71 and Xylesine
15 mg kg
71). After in situ measurements, the animals were sacri-
ﬁced and the tissue samples were collected and prepared for
ﬂuorescence microscopy analysis. The animals that received
labelled mTHPC were sacriﬁced at the same points in time as those
for LIFS and FM, and tissues were sampled for quantiﬁcation of
14C-mTHPC. All experiments were carried out following the
recommendation of guidelines for the welfare of animals in experi-
mental neoplasia (Workman et al, 1998) and in accordance with
the protocol approved by the Experimental Animal Ethics
Committee of the CHUV Hospital.
Deﬁnition and staging
‘Early stage’ SCCs were considered to be those that were either in
situ (Tis), i.e. intra-epithelial with no invasion of the basement
membrane, or micro-invasive (m-invasive SCC), i.e. with no inva-
sion beyond the lamina propria of the cheek pouch mucosa.
Between 6 and 9 weeks from the ﬁrst DMBA application, different
degrees of epithelial dysplasia were observed (Figure 1B), which
evolved to Tis and m-invasive SCCs (Figure 1C) between 10 and
12 weeks.
For advanced neoplastic lesions (Figure 1D), the tumour growth
was carefully observed after 12 weeks and documented weekly by
measurements of three axes (L6W6H). The animals were sacri-
ﬁced when tumours had reached a diameter no greater than 8–
10 mm, corresponding to a volume of 350 (+100) mm
3. All
tumours were well vascularised and free of necrosis at this size.
Macroscopic and histopathologic aspects of the normal hamster
pouch mucosa and steps of SC carcinogenesis from early to
advanced SCC are shown in Figure 1A–D (see legend to Figure
1). The histopathologic changes occurring during DMBA-induced
chemical carcinogenesis were highly reproducible in different
groups of animals. Macroscopically and microscopically, they were
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Figure 1 Macroscopic appearance on the left side and histology on the
right side of the hamster cheek pouch during various steps of squamous cell
carcinogenesis. (A) Smooth and uniform surface of the healthy cheek
pouch with thin mucosa; corresponding histology showing the top 3–4
layers of squamous epithelial cells (E) including well-delimited basal mem-
brane (BM); lamina propria (LP) containing stromal cells, ﬁbro-connective
tissue and blood vessels and underlying striated muscle (SM). (B) Early dys-
plastic changes varying from low- to high-grade dysplasia appear between 6
and 9 weeks after DMBA application. Macroscopically, the cheek pouch
mucosa is more-or-less thick, showing erythroleukoplastic changes. Histolo-
gically, this corresponds to an abnormal proliferation of epithelial cells with
large nuclei, abundant cytoplasm and frequent mitotic ﬁgures. BM is less
well delimited. No isolated tumour cells are visible in the lamina propria.
(C) About 10 weeks after DMBA application, erythroleucoplastic changes,
irregularity and thickening of the mucosa become much more severe. His-
tologically, besides the cytonuclear abnormalities, a small island of isolated
tumour cells appears in the lamina propria. This stage corresponds to m-in-
vasive carcinoma often associated with slight peritumoural inﬂammation.
(D) At 16 weeks following DMBA application, the bulky formation appears
on the painted cheek pouch surface, corresponding to more-or-less well-
differentiated SCC. At this stage, a tumour shows a highly inﬁltrative pat-
tern and large tumour nests invade the lamina propria and striated muscle.
The lesions are highly vascularised and tumour-associate inﬂammation is
abundant. Original magniﬁcation 610 (A,D) and 620 (B,C).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(12), 1470–1478very close to the human forms of ‘early stage’ (dysplasia, carcinoma
in situ or m-invasive carcinoma) and invasive SCCs in the upper
digestive tract and oesophagus (Andrejevic et al, 1996).
Photosensitiser
The mTHPC, now known under the trade name Foscan
1, as well
as its
14C-labelled form, were kindly supplied as a lyophilised
powder by Quanta-Nova (Guildford, UK). They were freshly
prepared before use by dissolving them in a mixture of 30%
(v v
71) polyethylene glycol 400, 20% (v v
71) ethanol and 50%
(v v
71)H 2O. mTHPC,
14C-labelled in the meso positions, was
custom-synthesised by American Radiolabeled Inc. (St. Louis,
MO, USA) with a speciﬁc activity of 74 mCi mmol
71 and a purity
at 97%.
Comparative pharmacokinetics study
After intracardiac injection of 0.5 mg kg
71 mTHPC or
14C-
mTHPC, groups of ﬁve tumour-bearing animals were sacriﬁced
at various points of time ranging from 4 h to 8 days. Before sacri-
ﬁce, non-invasive in situ LIFS measurements were performed in
animals injected with non-labelled mTHPC on various organs such
as the liver, kidney, healthy cheek pouch mucosa, early and
advanced SCC, striated (skeletal) and smooth muscle (uterus).
Then the blood was collected, the serum was separated by centri-
fugation and LIFS measurements of serum were carried out.
Following this step, the various tissue samples were fast frozen
and prepared for ﬂuorescence microscopy analysis. The animals
injected with
14C-mTHPC were sacriﬁced at the same times and
similar tissues were sampled for
14C-mTHPC quantiﬁcation.
In vivo pharmacokinetic measurements by LIFS Non-invasive
in vivo LIFS was performed with an optical ﬁbre-based spectroﬂuo-
rometer described previously (Zellweger et al, 1999). Brieﬂy, the
excitation light of a high-pressure xenon lamp was spectrally
ﬁltered by a spectrograph and coupled into an optical ﬁbre. This
ﬁbre was held in gentle contact with the tissue under investigation.
The emitted ﬂuorescence of the tissue was collected by the same
ﬁbre, separated from the excitation path by a dichroic ﬁlter and
spectrally dispersed by a second spectrograph. The ﬂuorescence
spectrum was recorded by a Peltier-cooled CCD camera and
processed by a microcomputer. A ﬂuorescence standard (Rhoda-
mine B, 1 mM in water) was used to calibrate the intensity of the
tissue ﬂuorescence for changes in excitation intensity and light
collection efﬁciency of the optical system. The absorption peak of
mTHPC at 420 nm was chosen as the excitation wavelength in
order to be sensitive essentially to the uppermost layers of mucosa.
The spectrum of the tissue autoﬂuorescence was subtracted from
the recorded spectrum. The height of the emission peak at
652 nm of the mTHPC ﬂuorescence was used as a relative measure
for the PS quantiﬁcation. The ﬂuorescence intensity obtained in
this way was reported in the corresponding ﬁgures in relative units
for in vivo ﬂuorescence (LIFS) (r.u. for 2a,3a,4a,5a) and for ex vivo
ﬂuorescence microscopy (FM) (r.u. for 2c,3c,4c,5c). For each tissue
of interest, we took 5–10 spectra by slightly displacing the ﬁbre on
the tissue in order to reduce the inﬂuence of local inhomogeneities.
The results were presented as mean values of these measurements
and are reported together with the corresponding standard devia-
tions.
Ex vivo ﬂuorescence microscopy-FM The biopsies taken were
fast frozen by contact with an isopentane slush and stored at
7708C prior to use. Tissue sections were prepared in the dark
to avoid photobleaching. Five consecutive non-stained 5-mm thick
tissue sections mounted on clean glass slides were prepared from
each sample. From each frozen section, three images were recorded
at three different parts of the slice to avoid photobleaching. The
autoﬂuorescence background substraction procedure was standar-
dised on tissue slices from ﬁve uninjected animals. The relative
ﬂuorescence intensity was analysed using the public domain NIH
Image 1.62 program. After recording the ﬂuorescence images, the
same slices were carefully removed and stained with haematoxilin
and eosin (HE). An HE image was recorded at an identical posi-
tion. The HE image was compared with the ﬂuorescence image
in order to determine the exact histological localisation of the PS
ﬂuorescence. We employed an Olympus BH-2 epiﬂuorescence
microscope with a ﬁltered 100 W mercury lamp as the excitation
light source. Fluorescence images were detected with a cooled
slow-scan 16-bit CCD camera (LEEV P86231, Wright Instruments,
Endﬁeld, UK). For excitation, an interference band pass ﬁlter
420DF30 and a dichroic mirror at 470 nm were used. A long pass
ﬁlter RG 630 was used to record the ﬂuorescence of mTHPC. An
interference band pass ﬁlter 560DF40 was used to record the tissue
autoﬂuorescence. The CCD camera was operated with an excitation
shutter to avoid photobleaching. The system was controlled by an
IBM-PC computer using the AT1 software (Wright Instruments),
which processes 16-bit images. The localisation and intensity of
the dye ﬂuorescence was ascertained by subtracting the autoﬂuor-
escence from the ﬂuorescence image. Flat ﬁeld correction was done
using a ﬂuorescent reference sample. The ﬂuorescence intensity
obtained in this way was reported in relative units (r.u.) in the
corresponding ﬁgures.
Chemical extraction of
14C-labelled mTHPC The time-depen-
dent presence of radioactivity in serum and various tissues was
determined after administration of 0.5 mg kg
71 mTHPC contain-
ing 55 mCi of
14C-labelled mTHPC. Speciﬁc activity of
14C-
mTHPC was calculated before the experiment. Each animal
received 5 mCi of
14C per 100 g of body weight. Animals were
sacriﬁced at the same points of time, as in the case of LIFS and
FM. The blood was collected, and the serum was separated after
centrifugation at 4000 g for 10 min. The various healthy tissues
of interest and tumours were surgically excised, rinsed in saline,
blotted dry and homogenised with scissors. The samples were
weighed and digested in 0.2 N NaOH (1 ml per 200 mg of homo-
genate) by shaking at 508C overnight. After digestion, the total
radioactive contents of each sample were determined in 4 ml of
scintillation liquid using a liquid scintillation counter and calcu-
lated as a per cent of total injected dose. Data were expressed in
mg of extracted
14C-labelled mTHPC g
71 of tissue. Background
radioactivity was measured using corresponding samples from
three animals that were administered unlabelled mTHPC. It never
exceeded 23 d.p.m. g
71 of tissue and was similar to that of scintil-
lation liquid alone.
Statistical analysis
The signiﬁcance of ﬂuorescence intensities at various points of
time, measured either by in vivo or ex vivo methods, was deter-
mined according to a non-parametric Mann–Whitney U-test
(a40.05). The results were presented as mean values of these
measurements and were reported together with the corresponding
standard deviations (s.d.). For extraction data, the mean concentra-
tion of ﬁve samples and their s.d. were calculated for each time
point. The data points were ﬁtted with the following function
(y=a exp (-bt) (1-exp (-ct))) for visual support.
RESULTS
The relative ﬂuorescence intensities or quantities of mTHPC
measured by the three methods showed a heterogeneous PS distri-
bution in different tissues at various times after administration.
The autoﬂuorescence level recorded on different tissues using LIFS
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British Journal of Cancer (2002) 87(12), 1470–1478 ã 2002 Cancer Research UKor FM was fairly comparable between different animals. It ranged
from 300 r.u. for striated muscle and 700 r.u. for ﬁbro-elastic
and collagen tissue of the lamina propria (data not shown). The
mTHPC ﬂuorescence and tissue distribution were within the same
order of magnitude at all measured points. Figures 2–5 display the
results of three evaluation methods in different organs and tissues
of interest.
Figure 2 illustrates a comparison of ﬂuorescence quantities
measured in serum by means of LIFS (Figure 2A), chemical extrac-
tion of
14C-labelled mTHPC (Figure 2B), as well as the relative
ﬂuorescence intensity recorded on normal blood vessel endothe-
lium by FM (Figure 2C). The highest mTHPC level in
endothelial cells of the blood vessels between 12 h and 1 day after
dye administration was observed by FM. The position of this maxi-
mum was compatible with the measurements obtained in the
serum using the two other mTHPC assessment techniques. After
1 day, the dye level decreased rapidly either in the serum or in
the vascular endothelium with an elimination lifetime between 2
and 3 days. It returned to background level at about 8 days after
administration. Fluorescence micrograph and corresponding HE
staining of the blood vessel wall 2 days after mTHPC administra-
tion are shown in Figure 2D. A much higher ﬂuorescence intensity
was observed in blood vessel endothelium than in adjacent struc-
tures such as ﬁbro-connective tissue of the lamina propria and
striated muscle.
The pharmacokinetics of mTHPC in the liver and kidney
presented similarities to those seen in the vasculature. Whatever
the method used, the highest dye amount was observed in liver
parenchyma and the excretory part of the kidney (glomerulus)
between 12 and 24 h after dye administration. The dye amount
decreased almost to the background level 96 h after administration
(Figure 3A–C).
The ﬂuorescence photomicrographs and the corresponding HE
stains in Figure 3D and E present the ﬂuorescence intensities in
the liver and kidney observed at 24 h after mTHPC administration.
The advantage of FM over the other two methods was that the PS
could be localised at the cellular level. As shown in Figure 3E, a
high mTHPC amount was observed in kidney glomerulus (white
area), and weak ﬂuorescence was recorded in proximal and distal
tubules of kidney parenchyma (dark area). This observation
suggests a rapid elimination of the dye from the excretory part
of the kidney. In order to compare the FM study in kidney to
the two other methods used, the mean ﬂuorescence intensity of
the whole kidney, including the glomerulus (excretory compart-
ment) and parenchyma (collecting compartment), was plotted
against time in Figure 3C.
A fairly similar kinetic pathway and no signiﬁcant selectivity in
mTHPC ﬂuorescence or quantity between healthy mucosa and
early SCC were observed by each of the three methods used (Figure
4). However, following a short delay after dye administration, a
signiﬁcant selectivity (a40.05) was noted between advanced SCC
and healthy mucosa. (deleted) (Figure 4A–C). The photomicro-
graphs and corresponding HE stains of healthy hamster mucosa
(Figure 4D), early (Figure 4E) and advanced SCC (Figure 4F)
recorded at 1 (advanced SCC) and 4 days (early SCC and healthy
mucosa) after mTHPC administration show a high ﬂuorescence in
either normal or tumoural epithelium. By contrast, weak ﬂuores-
cence intensity was observed in adjacent structures such as
underlying lamina propria, stromal endothelial cells and striated
muscle. The homogenous ﬂuorescence in the cytoplasm, surround-
ing the dark area corresponding to the nuclei, suggests an
intracellular localisation of mTHPC.
All three methods used in this study showed low time-depen-
dent mTHPC ﬂuorescence and a negligible quantity in striated
muscle (Figures 5A–C). By contrast, a signiﬁcantly higher
(a40.05) amount of ﬂuorescence or quantity was noted in smooth
muscle with a peak around 2 days after dye administration. Figure
5D,E show ﬂuorescence photomicrographs and corresponding HE
stains of striated and smooth muscle 3 days after mTHPC admin-
istration. Weak and negligible ﬂuorescence intensity was observed
in striated muscle, while a very high dye level was noted in smooth
muscle. Furthermore, apart from serum and liver, the maximum
mTHPC signal in smooth muscle between 2 and 3 days after
administration was signiﬁcantly higher than any signal seen in
other quantiﬁed tissues.
DISCUSSION
The present comparative study using LIFS and chemical extraction
of
14C-labelled mTHPC gives an overview and conﬁrms the phar-
macokinetic data in several tissues of interest relevant for clinical
PDT applications. The results presented here are in agreement with
the FM study reported previously by our group (Andrejevic Blant
et al, 1998, 2000). At a short delay (42 days) after injection, the
mTHPC was found in the liver, kidney, vasculature (either vascular
bed or serum) and advanced SCC. At longer delays, mTHPC was
mainly observed in the epithelial layer of the oral mucosa, and it
showed a particularly high afﬁnity for smooth muscle.
In contrast to the high mTHPC afﬁnity for smooth muscle, very
low dye ﬂuorescence was noted in striated muscle, stromal
endothelial cells and ﬁbro-connective tissue. One possible explana-
tion for this ﬁnding, observed by means of three different
evaluation approaches, could be a different embryogenic origin
of these tissues, and/or lipophilic properties and molecular struc-
ture of their cytoplasmic membrane. The ﬁbro-connective tissue
and striated muscle develops from endodermis, while smooth
muscles arise from the ectodermal germ layer. In addition, the
nerve supply of these two types of muscle is quite different. Motor
nerves supply the striated muscle, while a smooth muscle receives
its innervations from the autonomic nervous system by neuromus-
cular synapses on the membrane’s surface. The quantity and/or
disposition of lypophilic and hydrophilic surface-cell-membrane
molecules, ‘neurotransmitters’, are probably responsible for differ-
ent membrane charges and their consecutive afﬁnity for various
PS. From a clinical point of view, the low mTHPC level in striated
muscle provides the opportunity to develop interstitial PDT as a
minimally invasive treatment modality for more advanced SCC
of unfavourable localisation in the oral cavity or pharynx such as
the base of the tongue. It is also pertinent to note that PDT treat-
ment of the middle and lower oesophagus, which contains mostly
smooth muscle in its wall, should be treated with extreme caution
in order to avoid complications such as perforation and ﬁstula.
None of the methods used here permitted to ﬁnd a signiﬁcant
time-dependent selectivity between early SC malignancies and
healthy mucosa. However, at a short delay after mTHPC adminis-
tration, a signiﬁcant ﬂuorescence contrast (a40.05) was observed
between advanced SCC and healthy mucosa. Several histopatholo-
gical features observed in advanced SCC should explain in part this
selectivity. As with many human or animal tumours, the DMBA-
induced advanced SCC hamster model presents a large number
of tumour vessels as compared to healthy mucosa, as well as a
more-or-less severe peritumoural inﬂammatory reaction (Lurie et
al, 1983). In addition, the ultrastructural studies in human and
experimental animals have demonstrated an increased permeability
of tumour vessels (Feng et al, 2002).
All of these features should explain a much higher accumulation
of mTHPC shortly after administration in invasive SCC as
compared to normal tissue or early SCC. In our study, this was
supported by the mTHPC distribution in serum and advanced
SCC as shown in Figures 2 and 4. One can note that the half-life
of mTHPC in serum is between 2 and 3 days after injection
(Figure 2), whatever the method used, and that these points in
time coincide with the maximal mTHPC level in advanced SCC
(Figure 4).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(12), 1470–1478The results reported in this study are in good agreement with
results of biodistribution and pharmacokinetics of
14C-labelled
mTHPC in other rodent models (Whelpton et al, 1996; Obwege-
ser et al, 1998). Numerous studies on ex vivo or in vivo
quantiﬁcation of other ﬁrst and second-generation photosensiti-
sers such as phthalocyanines (Lee et al, 2001), photofrin
(Gomer and Dougherty, 1979), or aminolevulinic-acid induced
PPIX (Obwegeser et al, 1998), using similar evaluation methods
are also in agreement with the results reported in our study,
especially investigating the localisation of the PS in smooth
muscle.
It is important to note that measurements obtained by either
LIFS or ﬂuorescence microscopy may also be subject to errors from
environmental factors that affect the ﬂuorescence yield. For both
methods used, the ﬂuorochrome environment was the same for
all animals at various time intervals. This effect should thus not
affect our results as all of our samples, whether in vivo or ex vivo,
were processed following the same protocol.
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Figure 2 The comparative pharmacokinetics of mTHPC in serum and vascular endothelium by means of in situ LIFS (A), extraction of
14C-labelled
mTHPC (B) and ex vivo FM (C). The ﬂuorescence photomicrograph and corresponding HE staining of the blood vessel wall 48 h after mTHPC adminis-
tration shows a much higher ﬂuorescence intensity in blood vessel (V) endothelium as in adjacent structures such as ﬁbro-connective tissue (FC) of lamina
propria and striated muscle (SM) (D). Scale: the bar in the right bottom corner represents 20 mm.
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British Journal of Cancer (2002) 87(12), 1470–1478 ã 2002 Cancer Research UKIt is also well known that in situ LIFS measurements are highly
sensitive to the tissue type, as mentioned by several authors (Pouge
and Burke, 1998; Wagnie `res et al, 1998; Westermann et al, 1998).
In assessing the quantiﬁcation of ﬂuorescence in situ, it is necessary
to consider three major points: (a) the tissue’s optical properties of
the excitation and emission light; (b) the ﬂuorescence quantum
yield of the PS used in its environment and (c) the geometry of
the measurements. Indeed, if the ﬂuorescence quantum yield of
the PS changes with the environment of the latter, then the ﬂuor-
escence signal and the corresponding PS concentration are no
longer related in the same manner. Some of these points have been
studied in detail by our group using mTHPC and its PEG-coupled
form on a human xenograf colon carcinoma model. A good corre-
lation between LIFS, quantiﬁcation of radioactivity and
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
5 10 100 200
Time after injection (h)
8000
6000
4000
2000
0
liver
kidney
F
l
u
o
r
e
s
c
e
n
c
e
 
i
n
t
e
n
s
i
t
y
 
(
r
.
u
.
 
f
o
r
 
2
a
,
3
a
,
4
a
,
5
a
)
1.5
1
0.5
0
5 10 100 200
Time after injection (h)
1
4
C
-
m
T
H
P
C
u
g
/
–
1
g
 
o
f
 
t
i
s
s
u
e
5 10 100 200
Time after injection (h)
14000
12000
1000
8000
6000
4000
2000
0
F
l
u
o
r
e
s
c
e
n
c
e
 
i
n
t
e
n
s
i
t
y
 
(
r
.
u
.
 
f
o
r
 
2
c
,
3
c
,
4
c
,
5
c
)
A
B
C
E
liver
kidney
liver
kidney
D
Figure 3 The comparative pharmacokinetics of mTHPC in the liver and kidney using in situ LIFS (A), extraction of
14C-labelled mTHPC (B) and ex vivo
FM (C). Fluorescence photomicrographs and corresponding HE stains show the high ﬂuorescence intensity, uniform in liver parenchyma (D) and kidney
glomerulus (white areas), while a low dye amount was observed in proximal and distal tubes of kidney parenchyma (dark area) soon (24 h) after mTHPC
administration (E). Scale: the bar in the right bottom corner represents 20 mm.
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Figure 4 The comparative pharmacokinetics of mTHPC in healthy mucosa, early and advanced SCC observed by in situ LIFS (A), extraction of
14C-la-
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(F) show high ﬂuorescence intensity in the epithelial layers in both normal or tumoural epithelium (E), while adjacent structures such as underlying lamina
propria (LP) and striated muscle (SM) show a weak ﬂuorescence intensity. Scale: the bar in the right bottom corner represents 20 mm.
Comparative pharmacokinetics of mTHPC in hamster model
S Andrejevic Blant et al
1476
British Journal of Cancer (2002) 87(12), 1470–1478 ã 2002 Cancer Research UKimprovement of in vivo tumour localisation reported by Wester-
mann et al (1998) are in good agreement with our study.
The measured values obtained by LIFS and FM as well as
quantities of extracted mTHPC in different analysed tissues allow
us to conclude that there is a highly reproducible ‘quantitative
correlation’ between different tissues of interest. The ratios of
nearly 3:1 between advanced SCC and normal mucosa and 7:1
between smooth and striated muscle were observed by all three
methods.
One of the major unresolved issues in PDT research is the devel-
opment of optimal dosimetry tools useful for photosensitiser
quantiﬁcation in situ. Our study has shown that any of the three
methods should be suitable either when used together or separately
for preclinical screening of new generation PS, as long as the ther-
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tration.
Two main conclusions resulting from this study are that the
LIFS measurements are conﬁrmed by absolute concentration of
14C-labelled mTHPC, and that ex vivo FM measurements are in
agreement with in vivo LIFS data. This permits us to develop
concept of ‘validation’ of ex vivo techniques by in vivo LIFS
measurements. The observed correlations support the hypothesis
that non-invasive in vivo LIFS provide real-time information useful
for adapting light dosimetry for each patient treated by PDT, in
order to avoid under or over treatment and undesirable side
effects. Therefore, LIFS for individualised in vivo dosimetry is a
promising in situ technique, which needs to be improved upon
by evaluating a large number of therapeutic results.
We hope that individualised dosimetry will be relevant for a better
understanding of the distribution and kinetics of new photosensiti-
sers and thus will contribute to increasing the efﬁcacy of clinical
trials. This assumes that the best therapeutic results will be obtained,
side effects will be diminished, and complications will be avoided.
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